MOLECULAR EXPRESS, INC
Federal contract awards won by MOLECULAR EXPRESS, INC (UEI R1JMHFESEKD5), 2020–2024 — public record from USAspending.
Showing awards with a value or ceiling of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
8
awards
1
expiring in 12 months
1
agency
Category award history
5 category awards to a new vendor (same agency and NAICS code, not this contract's own history) — latest: SRI INTERNATIONAL took Department of Health and Human Services 541715 work from MOLECULAR EXPRESS, INC (Aug 31, 2026).
Agencies buying from MOLECULAR EXPRESS, INC
What MOLECULAR EXPRESS, INC has provided
Awards
VESIVAX TLR7 FORMULA
Department of Health and Human Services · $2,999,352 · Sep 1, 2024
DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS
Department of Health and Human Services · $1,999,866 · Jul 1, 2024
DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
Department of Health and Human Services · $599,925 · Sep 30, 2023
THE CONTRACTOR SHALL TO ENGINEER NOVEL HIV GP41 ECTODOMAIN ANTIGENS (HIV GP41E-HD) FOR THE INCORPORATION INTO THE IMMUNOGENIC VESIVAX FORMULATIONS.
Department of Health and Human Services · $300,000 · Jul 1, 2022
DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION
Department of Health and Human Services · $569,807 · Aug 1, 2021
THE CONTRACTOR SHALL TO EVALUATE THE DIFFERENT CO-DELIVERY METHODS OF A MODEL HIV ANTIGEN USING THE VESIVAX LIPOSOMAL PLATFORM.
Department of Health and Human Services · $2,294,565 · Jul 1, 2021
THE OBJECTIVE OF THIS CONTRACT IS TO IDENTIFY A POTENTIAL HIV ANTIGEN-CONJUGATED VACCINE FORMULATION BY EXPLORING CO-DELIVERY OF HIV ANTIGENS AND ADJUVANT MOLECULES.
Department of Health and Human Services · $299,961 · Jun 1, 2020
THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A VESIVAX PLATFORM-BASED LIPOSOMAL FORMULATION THAT WILL EFFICIENTLY DISPLAY THE HIV IMMUNOGEN.
Department of Health and Human Services · $299,993 · Jun 1, 2020